| Literature DB >> 32692317 |
Mahzad Akbarpour1, Emilia Lecuona1, Stephen F Chiu1, Qiang Wu1, Melissa Querrey1, Ramiro Fernandez1, Félix L Núñez-Santana1, Haiying Sun1, Sowmya Ravi1, Chitaru Kurihara1, James M Walter2, Nikita Joshi2, Ziyou Ren2, Scott C Roberts3, Alan Hauser2,3, Daniel Kreisel4,5, Wenjun Li4, Navdeep S Chandel2, Alexander V Misharin2, Thalachallour Mohanakumar6, G R Scott Budinger2, Ankit Bharat1,2.
Abstract
Despite the widespread use of antibiotics, bacterial pneumonias in donors strongly predispose to the fatal syndrome of primary graft dysfunction (PGD) following lung transplantation. We report that bacterial endotoxin persists in human donor lungs after pathogen is cleared with antibiotics and is associated with neutrophil infiltration and PGD. In mouse models, depletion of tissue-resident alveolar macrophages (TRAMs) attenuated neutrophil recruitment in response to endotoxin as shown by compartmental staining and intravital imaging. Bone marrow chimeric mice revealed that neutrophils were recruited by TRAM through activation of TLR4 in a MyD88-dependent manner. Intriguingly, low levels of endotoxin, insufficient to cause donor lung injury, promoted TRAM-dependent production of CXCL2, increased neutrophil recruitment, and led to PGD, which was independent of donor NCMs. Reactive oxygen species (ROS) increased in human donor lungs starting from the warm-ischemia phase and were associated with increased transcription and translocation to the plasma membrane of TLR4 in donor TRAMs. Consistently, scavenging ROS or inhibiting their production to prevent TLR4 transcription/translocation or blockade of TLR4 or coreceptor CD14 on donor TRAMs prevented neutrophil recruitment in response to endotoxin and ameliorated PGD. Our studies demonstrate that residual endotoxin after successful treatment of donor bacterial pneumonia promotes PGD through ischemia/reperfusion-primed donor TRAMs.Entities:
Keywords: Bacterial infections; Immunology; Macrophages; Organ transplantation; Transplantation
Mesh:
Substances:
Year: 2020 PMID: 32692317 PMCID: PMC7410086 DOI: 10.1172/JCI135838
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808